7.0/10
Moderate

CJC-1295

CJC-1295 · GHRH analog · Growth Hormone / Recovery

The GHRH analog with real pathway signal and wildly inflated physique expectations. Better as a protocol tool than a personality trait. Legit, still not HGH.

Cost / mo
$90–160
Forms
SubQ
Onset
2–4 weeks
Cycle
8–12 weeks
Studies
10+

Should you care about CJC-1295?

You should care if you're building a deliberate GH-support protocol and want a compound with actual human pharmacology behind it. CJC-1295 is not fake signal.

You should stay grounded because pathway activation is not the same thing as dramatic outcome data. Higher GH and IGF-1 do not automatically cash out as visible body-composition wins.

What the internet says

"CJC-1295 is basically legal HGH."

What the data says

No. It stimulates endogenous GH release upstream. That matters biologically and still does not make it equivalent to prescribed GH therapy.

What it actually does (ranked by evidence)

1

GH and IGF-1 SupportModerate

This is the cleanest use case and the strongest argument for the compound. Human pharmacology backs target engagement.

2

Sleep and Recovery SupportModerate

Often useful inside a broader protocol, especially when the rest of recovery hygiene is already locked in.

3

Body-Composition SupportWeak

Possible, inconsistent, and almost always overstated when the compound is sold as a shortcut.

Dosing

This is endocrine tinkering, not wellness tea. DAC and non-DAC behave differently, so sloppy protocol talk gets expensive fast.
Oral
No standard oral form

CJC-1295 is not the peptide for people trying to avoid injections altogether.

Injectable
100–300 mcg up to 1–2 mg

Non-DAC is pulsed more often. DAC versions are spaced out. Pretending they're the same compound is a reliable way to misunderstand both.

Most people care less about the chemistry distinction than they should. The chemistry distinction is basically the protocol.

Side effects: the honest version

What the internet says

"If you can tolerate DAC, more exposure always means better results."

What the data says

Not necessarily. Longer exposure can also mean more edema, more headache, and more protocol noise.

✓ Confirmed safe
  • ✓Water retention
  • ✓Flushing or tingling after dosing
  • ✓Headache or transient dizziness
! Unknown
  • iDAC exposure can make side effects more persistent when a dose is too aggressive.
  • iInsulin sensitivity and appetite shifts can complicate longer protocols.
  • iHigher IGF-1 is a biomarker shift, not proof of a better outcome.

The studies that matter

We read all 10+. These are the three we'd cite first.

CJC-1295 with DAC increases GH and IGF-1 in healthy adults

Moderate
Clinical endocrinology literature · 2006
Result: Clear endocrine target engagement with longer exposure than short-acting GHRH analogs

Short-acting GHRH analog pulse studies

Moderate
Endocrine pharmacology studies · 2000s
Result: Useful pulse support, more dosing friction, and less mythology than message boards prefer

Body-composition extrapolations from GH-axis biomarker shifts

Weak
Small open-label and translational reports · 2010s
Result: Outcome claims remain softer than the biomarker story
View all 10+ studies

How it stacks up

Growth Hormone peptide comparison. No hedging.

CJC-1295
Ipamorelin
Sermorelin
Score
7.0
7
7.5
Evidence
Moderate
Moderate
Moderate
Oral?
No
No
No
Cost / mo
$90–160
$80–140
$90–150
Best for
Growth hormone and IGF-1 support
Cleaner GH pulses
Conservative GH support
Our pick?
Situational
Great stack
Milder

Questions people actually ask

Answers that don't insult your intelligence.

DAC refers to a drug-affinity complex that extends how long the peptide stays active. That changes both dosing frequency and side-effect dynamics.
★ Bottom Line

CJC-1295 has real endocrine activity and very online marketing. Useful if you understand what GH signaling can and cannot buy you. Less impressive if you're shopping for magic.

— PepTalk Editorial Team · March 2026